Form 4 for DSGN Design Therapeutics, Inc.
Accepted 2024-08-12 00:00:00 ET · period of report 2024-08-09 · accession 0001415889-24-021086 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-08-12 | 2024-08-09 | DSGN | William Arsani | Dir | S - Sale | $4.25 | -814.9K | 0 | -100% | -$3.46M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-09 | S | D | 814,874 | $4.25 | 0 | I By Logos SPV I LP | — | — | (F1) Logos Global Management LP is the investment advisor of private funds, including Logos Opportunities Fund II LP ("LOF II") and Logos SPV 1 LP ("SPV 1"). Logos Opportunities GP LLC ("GP I") is the general partner of LOF II. Logos Opportunities II GP LLC ("GP II") is the general partner of SPV 1. The Reporting Person is the Managing Member of both GP I and GP II. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |